These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 19089422)
1. False-negative thyroglobulin measurement in recurrent/metastatic thyroid carcinomas. Giovanella L Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):326-7; author reply 328. PubMed ID: 19089422 [No Abstract] [Full Text] [Related]
2. Undetectable thyroglobulin in patients with differentiated thyroid carcinoma and residual radioiodine uptake on a postablation whole-body scan. Giovanella L; Suriano S; Ceriani L; Verburg FA Clin Nucl Med; 2011 Feb; 36(2):109-12. PubMed ID: 21220971 [TBL] [Abstract][Full Text] [Related]
3. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. Park EK; Chung JK; Lim IH; Park DJ; Lee DS; Lee MC; Cho BY Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):172-9. PubMed ID: 18779963 [TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. Shammas A; Degirmenci B; Mountz JM; McCook BM; Branstetter B; Bencherif B; Joyce JM; Carty SE; Kuffner HA; Avril N J Nucl Med; 2007 Feb; 48(2):221-6. PubMed ID: 17268018 [TBL] [Abstract][Full Text] [Related]
5. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493 [TBL] [Abstract][Full Text] [Related]
6. Relative value of thallium-201 and iodine-131 scans in the detection of recurrence or distant metastasis of well differentiated thyroid carcinoma. Lin JD; Kao PF; Weng HF; Lu WT; Huang MJ Eur J Nucl Med; 1998 Jul; 25(7):695-700. PubMed ID: 9662590 [TBL] [Abstract][Full Text] [Related]
7. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan. Trybek T; Kowalska A; Lesiak J; Młynarczyk J Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108 [TBL] [Abstract][Full Text] [Related]
8. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959 [TBL] [Abstract][Full Text] [Related]
10. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan? Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540 [TBL] [Abstract][Full Text] [Related]
11. Histology and immunocytochemistry of differentiated thyroid carcinomas do not predict radioiodine uptake: a clinicomorphological study of 62 recurrent or metastatic tumours. Bätge B; Dralle H; Padberg B; von Herbay B; Schröder S Virchows Arch A Pathol Anat Histopathol; 1992; 421(6):521-6. PubMed ID: 1466156 [TBL] [Abstract][Full Text] [Related]
12. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315 [TBL] [Abstract][Full Text] [Related]
13. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study. Franke WG; Zöphel K; Wunderlich GR; Mat R; Kühne A; Schimming C; Kropp J; Bredow J Cancer Detect Prev; 2000; 24(6):524-30. PubMed ID: 11198265 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level. Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605 [TBL] [Abstract][Full Text] [Related]
16. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Rothenberg SM; McFadden DG; Palmer EL; Daniels GH; Wirth LJ Clin Cancer Res; 2015 Mar; 21(5):1028-35. PubMed ID: 25549723 [TBL] [Abstract][Full Text] [Related]
17. The role of routine diagnostic radioiodine whole-body scintigraphy in patients with high-risk differentiated thyroid cancer. de Meer SG; Vriens MR; Zelissen PM; Borel Rinkes IH; de Keizer B J Nucl Med; 2011 Jan; 52(1):56-9. PubMed ID: 21149483 [TBL] [Abstract][Full Text] [Related]
18. [Thyroglobulin as a tumor marker and thallium scintigraphy for the course control of differentiated thyroid cancer]. Müller-Brand J; Fridrich R; Spicher E; Staub JJ Schweiz Med Wochenschr; 1983 Mar; 113(9):325-7. PubMed ID: 6844904 [TBL] [Abstract][Full Text] [Related]
19. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma. Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882 [TBL] [Abstract][Full Text] [Related]
20. Thyroglobulin in patients with differentiated thyroid carcinoma. Lindegaard MW; Paus E Scand J Clin Lab Invest Suppl; 1991; 206():79-84. PubMed ID: 1947763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]